Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.72 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.68 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.63 |
| ▸ | SMYD2 | Q9NRG4 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | MITF | O75030 | 1/20 | 0.57 |
| ▸ | DRD2 | P14416 | 1/20 | 0.57 |
| ▸ | DRD4 | P21917 | 1/20 | 0.57 |
| ▸ | ERN1 | O75460 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | RAD52 | P43351 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL842621 | 0.99 | HSD17B10 (0.70) | HSD17B10NPSR1CACNA1GSMYD2KMT2A | |
| SCHEMBL5482155 | 0.91 | SMYD2 (0.68) | HSD17B10NPSR1CACNA1GSMYD2KMT2A | |
| SCHEMBL279958 | 0.88 | CYP2C19 (0.72) | HSD17B10ALDH1A1CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL10720723 | 0.86 | HSD17B10 (0.68) | HSD17B10SMYD2KMT2AMEN1NPC1 | |
| SCHEMBL12334148 | 0.84 | NPSR1 (0.58) | NPSR1CACNA1GSMYD2KMT2AMEN1 | |
| SCHEMBL4766997 | 0.83 | CYP2C9 (0.57) | NPSR1SMYD2KMT2AMEN1ALDH1A1 | |
| SCHEMBL4572856 | 0.83 | CYP2C9 (0.57) | NPSR1SMYD2KMT2AMEN1ALDH1A1 | |
| SCHEMBL4268373 | 0.83 | MAPT (0.73) | NPSR1KMT2AMEN1NPC1RAB9A | |
| SCHEMBL12057347 | 0.83 | TP53BP1 (0.57) | HSD17B10NPSR1SMYD2KMT2AMEN1 | |
| SCHEMBL12203378 | 0.83 | MEN1 (0.76) | HSD17B10NPSR1SMYD2KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9328067-B2 | Sulfur derivatives as chemokine receptor modulators | ALLERGAN, INC. (US) | 2016-05-03 | — | — | US | claimed |
| US-20130252984-A1 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2013-09-26 | — | — | US | claimed |
| US-11759462-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | ALTAVANT SCIENCES GMBH | 2023-09-19 | — | — | US | disclosed |
| US-11046644-B2 | Sulfur derivatives as chemokine receptor modulators | ALLERGAN, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| US-20200109110-A1 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN INC (US) | 2020-04-09 | — | — | US | disclosed |
| US-10287243-B2 | Sulfur derivatives as chemokine receptor modulators | ALLERGAN, INC. (US) | 2019-05-14 | — | — | US | disclosed |
| US-20180092918-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | ALTAVANT SCIENCES GMBH (CH) | 2018-04-05 | — | — | US | disclosed |
| US-9750740-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | Kanos Pharmaceuticals, Inc. (US) | 2017-09-05 | — | — | US | disclosed |
| US-20170095476-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | ALTAVANT SCIENCES GMBH (CH) | 2017-04-06 | — | — | US | disclosed |
| US-9512122-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | KAROS PHARMACEUTICALS, INC. (US) | 2016-12-06 | — | — | US | disclosed |
| US-9328067-B2 | Sulfur derivatives as chemokine receptor modulators | ALLERGAN, INC. (US) | 2016-05-03 | — | — | US | disclosed |
| US-20150080393-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | ALTAVANT SCIENCES GMBH (CH) | 2015-03-19 | — | — | US | disclosed |
| US-20140356760-A1 | NITROGEN-CONTAINING CARBON ALLOY, METHOD FOR PRODUCING SAME, CARBON ALLOY CATALYST, AND FUEL CELL | FUJIFILM CORPORATION (JP) | 2014-12-04 | — | — | US | disclosed |
| US-20130252984-A1 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-8431713-B2 | 2-aminopyridine derivatives as glucokinase activators | ARRAY BIOPHARMA, INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-8134013-B2 | Amide compound and thrombopoietin receptor activator | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2012-03-13 | — | — | US | disclosed |
| US-8134013-B2 | Amide compound and thrombopoietin receptor activator | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2012-03-13 | — | — | US | disclosed |
| US-20090131659-A1 | AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2009-05-21 | — | — | US | disclosed |
| US-20090131659-A1 | AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2009-05-21 | — | — | US | disclosed |
| EP-1845090-A1 | AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | Nissan Chemical Industries, Ltd. (JP) | 2007-10-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150080393-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | TPH1, TPH2, HTR1A | HSD17B10 287/4885NPSR1 205/4885CACNA1G 2221/4885 |
| US-20180092918-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | TPH1, TPH2, HTR1A | HSD17B10 287/4885NPSR1 205/4885CACNA1G 2221/4885 |
| US-20170095476-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | TPH1, TPH2, HTR1A | HSD17B10 287/4885NPSR1 205/4885CACNA1G 2221/4885 |
| US-20090131659-A1 | AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | TEK, PTAFR, MPL | HSD17B10 4112/4885NPSR1 168/4885CACNA1G 3638/4885 |
| US-11759462-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | TPH1, TPH2, HTR1A | HSD17B10 287/4885NPSR1 205/4885CACNA1G 2221/4885 |
| US-20200109110-A1 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | CX3CR1, CXCR2, CCR2 | HSD17B10 3237/4885NPSR1 34/4885CACNA1G 4720/4885 |
| US-20130252984-A1 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | CX3CR1, CXCR2, CCR2 | HSD17B10 3237/4885NPSR1 34/4885CACNA1G 4720/4885 |
| US-10287243-B2 | Sulfur derivatives as chemokine receptor modulators | CX3CR1, CXCR2, CCR2 | HSD17B10 3237/4885NPSR1 34/4885CACNA1G 4720/4885 |
| US-11046644-B2 | Sulfur derivatives as chemokine receptor modulators | CX3CR1, CXCR2, CCR2 | HSD17B10 3237/4885NPSR1 34/4885CACNA1G 4720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.